Symbol | Exchange | Currency |
|---|
Cytokinetics (CYTK) has priced its underwritten public offering of 10M common shares at $27.50/share for total gross proceeds of ~$275M.Underwriters granted 30-days option to...
Cytokinetics Incorporated (NASDAQ: CYTK) shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments from...
After a 40.4% rise on Monday, Cytokinetics (CYTK) has continued the upward trajectory with a ~5.3% gain in pre-market as Wall Street becomes increasingly bullish on the company...
Monday was a good day to be a Cytokinetics (CYTK) investor. On what was a down day for the markets across the board, shares took off to the tune of 40% after the company announced...
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from a secondary analysis of GALACTIC-HF...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,727.80 | 2,765.00 | 2,706.70 | +89.8 | +3.40% | 2.92M | NASDAQ | |||
| 372.88 | 377.54 | 367.00 | +5.07 | +1.38% | 12.59M | NASDAQ | |||
| 195.27 | 196.46 | 189.95 | +3.19 | +1.66% | 12.23M | NASDAQ | |||
| 43.57 | 43.73 | 42.26 | +1.47 | +3.49% | 29.87M | NYSE | |||
| 194.50 | 196.40 | 189.76 | +8.43 | +4.53% | 23.04M | NYSE | |||
| 68.70 | 68.86 | 67.01 | +1.21 | +1.79% | 4.44M | NYSE | |||
| 15.84 | 16.32 | 14.02 | +3.11 | +24.43% | 90.76M | NASDAQ | |||
| 53.19 | 53.92 | 52.94 | +0.01 | +0.02% | 15.56M | NASDAQ | |||
| 41.47 | 41.87 | 39.80 | +2.11 | +5.36% | 44.18M | NYSE | |||
| 0.8615 | 0.00 | 0.00 | +0.0755 | +9.61% | 158.37M | NASDAQ | |||
| 39.27 | 39.55 | 36.08 | +1.26 | +3.31% | 51.68M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 21.21 | 21.21 | 20.91 | +0.22 | +1.05% | 5.01M | NYSE | |||
| 8.92 | 9.46 | 6.95 | +3.030 | +51.44% | 93.58M | NASDAQ | |||
| 20.47 | 20.65 | 20.16 | +0.11 | +0.54% | 4.05M | NYSE |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
